No insider purchase over the last 90 days. The latest was filed 29 Dec 2025.
Every trade that managers of Inventurus Knowledge Solutions Limited disclose to SEBI (PIT + SAST) is tracked on this page. The company sits in the Health Care sector. The last twelve months, up to 18 October 2026, brought 59 filings signed by 32 insiders.
There is no open-market purchase to report; the filings show 43 sales worth €13.6M by 23 insiders. The largest single trade was a sale of €1.9M by Kashyap Khadashankar Joshi, published on 7 November 2025.
Between a trade and the moment it shows up on SEBI (PIT + SAST), the median delay is 1 day. That lag is the time during which only the insider knows about the trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
With 59 filings in twelve months, the company is more active than the median of 4 filings across the 1,985 companies we follow on the same exchange. Since 2024, the database holds 34 purchases and 101 sales by insiders of the company.
In the same sector, recent insider purchases at MAIA Biotechnology, Inc. and Cooper Companies, Inc. also feature in our signals. Every figure here comes from the filings published by SEBI (PIT + SAST) and describes the past, not future prices; it is not investment advice.
+53 other insiders
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analysts rate Inventurus Knowledge Solutions Limited Buy (bullish), based on 9 analysts. Average price target: ₹2,023.33.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended March 2026 · cache
25 of 136 declarations
Inventurus Knowledge Solutions Limited is a company specializing in knowledge management solutions for the healthcare and pharmaceutical sector. It operates in the XBOM market.